Mirdametinib (Standard)

Overview

Mirdametinib (Standard) is the analytical standard of Mirdametinib ( HY-10254 ). This product is intended for research and analytical applications. Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC 50 of 0.33 nM. Mirdametinib exhibits a Kiapp of 1 nM against activated MEK1 and MEK2 . Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis . Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts.

Application

Products | Products > Signaling Pathways > Others | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > MEK | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-10254R
• CAS No.: 391210-10-9
• Molecular Formula: C16H14F3IN2O4
• Molecular Weight: 482.19
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source